Vesiculobullous autoimmune diseases with oral mucosa manifestations: retrospective and follow-up study

Abstract

Objective: To conduct a retrospective study on a series of cases of PV and BMMP with manifestations in the oral cavity in order to ascertain prevalence, sociodemographic characteristics, diagnostic maneuvers, treatment and follow-up. Methods: This is a retrospective, descriptive study in which clinical data were collected from the medical records of all cases of PV and BMMP registered and diagnosed, between 1995 and 2015, in the Oral Diagnostic Service of the UFRN Department of Dentistry. Results: The mean age of the total sample (n = 36) was 41.64, with females the most frequent (n = 26; 72.22%) and the cheek mucosa being the site most affected (n = 20; 27.40%). Eight patients (22.22%), including 5 cases of PV and 3 BMMP, were clinically reevaluated. All patients exhibited lesions at the time of follow-up. Prednisone (n=7; 87.5%) and clobetasol propionate (n=8, 100%) were the most widely used drugs in the systemic and topical treatment, respectively. The follow-up period ranged from 5 months to 5 years. Conclusion: The clinical profile of patients in this study was similar to that evidenced in the literature. However, it was found that the oral lesions were more resistant to the treatment used on the patients evaluated.

Prevalence of oral mucosal lesions in patients with pemphigus vulgaris: A systematic review and meta‐analysis

“…The studies were conducted in 20 countries: Argentina, 7 Brazil, 15,16 Croatia, 17 Egypt, 18 Greece, 19 India, 6,20–23 Iran, 24–29 Italy, 2,3,30 Japan, 31 Korea, 32 Kuwait, 33 Macedonia, 34 Mexico, 35 Morocco, 8,36 Romania, 37 Serbia and Montenegro, 38 Slovakia, 39 Spain, 40,41 Thailand, 42 and Turkey 1,5,9,43–45 . Years of publication ranged from 1999 33 to 2020 3,4,6–9,24 .…”

“…The PV diagnosis was conducted under clinical examinations and histopathological analysis. Additionally, in all but two included studies 15,23 further examinations through either DIF, IFF, or ELISA were conducted. The main indexes to assess activity of disease were the Pemphigus Disease Area Index (PDAI), and the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) to measure and capture changes in PV severity, which are important tools that provide quantitative and qualitative data on the severity of disease and response to treatment.…”

Descrição de tratamento para pênfigo vulgar: relato de caso

“…No caso apresentado, foi administrado este medicamente com dosagem superior (prednisona 80mg) combinado com um imunossupressor (azatioprina 100 mg/dia), o que é defendido por Robinson, Lozada-Nur, Frieden 19 e Gonçalo et al 1 . Para estes autores as taxas de mortalidade são de 70,5% antes do estabelecimento de terapia sistêmica com corticóides, apenas 21,4% com o uso de corticosteroides e 3,7% quando os corticoides são combinados com outros imunossupressores.…”

“…O pênfigo vulgar é uma doença dermatológica, a qual é ativada pelo o sistema imunológico contra constituintes do próprio organismo. É um tipo de manifestação clínica grave e interfere diretamente na qualidade de vida do sujeito, sendo por isso ainda um alvo de intensa investigação, uma vez que desafia o cirurgião dentista a um diagnóstico precoce e tratamento adequado [1][2] .…”

Manifestação Oral De Lesão Penfigóide - Relato De Caso E Revisão Da Literatura

“…Já os corticosteróides sistêmicos são a opção de tratamento de primeira linha para pacientes o estado grave da doença, com rápido progresso e aqueles que não reagem às terapias iniciais. Normalmente a dosagem pode alterar de acordo com o quadro clínico do paciente e pode ser iniciada em 0,5 mg/kg/ dia para situações moderadas, chegando a 1-2mg/kg/ dia para situações mais graves 30,31 .…”